Clark Capital Management Group, Inc.
Position in RPRX — Royalty Pharma plc
CIK 1352187
PHILADELPHIA, PA
Position in RPRX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$78,669,264
+$10,902,046 QoQ
Shares Held
1,639,968
-6.5% QoQ
Ownership
0.285%
of shares outstanding
% of Portfolio
0.66%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in RPRX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Clark Capital Management Group, Inc. holds $130,946,596 across 6 Biotechnology names. RPRX ranks #1 (60.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RPRX |
Royalty Pharma plc
This page
|
1,639,968 | $78,669,264 | |
| 2 | LGND |
Ligand Pharmaceuticals Inc
|
90,206 | $18,009,627 | |
| 3 | CPRX |
Catalyst Pharmaceuticals, Inc.
|
568,676 | $14,080,417 | |
| 4 | HALO |
Halozyme Therapeutics, Inc.
|
214,102 | $13,837,412 | |
| 5 | EXEL |
Exelixis, Inc.
|
142,980 | $6,132,412 | |
| 6 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
487 | $217,464 |
All Filings in RPRX
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $78,669,264 | 1,639,968 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $67,767,218 | 1,753,810 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $61,804,985 | 1,751,842 | Shares | Sole | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||